The Application of Biomarkers in the Care of Patients With Atrial Fibrillation
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 266
- 试验地点
- 1
- 主要终点
- Novel biomarkers
研究概览
简要总结
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3.
Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
详细描述
With an aging population and advances in medical care, the prevalence of atrial fibrillation (AF) continues to rise. Although the introduction of novel oral anticoagulants has reduced the risk of stroke, AF can still lead to myocardial ischemia, fibrosis, and ultimately heart failure and valvular dysfunction. Given its often paroxysmal nature, the diagnosis and assessment of AF burden remain challenging and frequently rely on prolonged electrocardiographic monitoring.
Identifying accessible and reliable blood-based biomarkers could provide a cost-effective alternative to time-consuming and expensive wearable or implantable monitoring devices, offering significant clinical value.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Who have signed up for the Protocol No. 202003090RINA(National Taiwan University Hospital Atrial Fibrillation Integrated Care Pilot Program)
排除标准
- •Subjects without complete pre- and post-treatment testing
研究组 & 干预措施
afib
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3.
Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
结局指标
主要结局
Novel biomarkers
时间窗: 1YEARS
Whether novel biomarkers are associated with atrial fibrillation burden and could serve as tools to assist clinicians in diagnosing and treating patients, including tracking treatment effectiveness or the timeline for progression to heart failure;
次要结局
未报告次要终点